Evidence map›Paper›PMID 41294704›Full record

ArticleCurrent oncology (Toronto, Ont.)2025

Complications of Robotic Pelvic Lymph Node Dissection for Prostate Cancer: An Analysis of the National Surgical Quality Improvement Program Targeted Prostatectomy Database.

Vatsala Mundra, Renil S Titus, Eusebio Luna-Velasquez, Jiaqiong Xu, Carlos Riveros, Sanjana Ranganathan, Aamuktha Porika, Brian J Miles, Dharam Kaushik, Christopher J D Wallis and 1 more

Abstract read
In one paragraph

Article in Current oncology (Toronto, Ont.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Vatsala MundraDepartment of Urology, Houston Methodist Hospital, Houston, TX 77030, USA.
Renil S TitusDepartment of Urology, Houston Methodist Hospital, Houston, TX 77030, USA.
Eusebio Luna-VelasquezDepartment of Urology, Houston Methodist Hospital, Houston, TX 77030, USA.
Jiaqiong XuCenter for Health Data Science and Analytics, Houston Methodist Research Institute, Houston, TX 77030, USA.ORCID 0000-0002-3463-2327
Carlos RiverosDepartment of Urology, Houston Methodist Hospital, Houston, TX 77030, USA.
Sanjana RanganathanDepartment of Urology, Houston Methodist Hospital, Houston, TX 77030, USA.
Aamuktha PorikaDepartment of Urology, Houston Methodist Hospital, Houston, TX 77030, USA.
Brian J MilesDepartment of Urology, Houston Methodist Hospital, Houston, TX 77030, USA.
Dharam KaushikDepartment of Urology, Houston Methodist Hospital, Houston, TX 77030, USA.ORCID 0000-0002-1942-2743
Christopher J D WallisDivision of Urology and Surgical Oncology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON M5S 1A1, Canada.ORCID 0000-0002-5990-4026
Raj SatkunasivamDepartment of Urology, Houston Methodist Hospital, Houston, TX 77030, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

INTRODUCTION/

backgroundTreatment of localized prostate cancer includes radical prostatectomy (RP) with or without pelvic lymph node dissection (PLND). While multiple guidelines recommend PLND for staging purposes, recent data has shown questionable therapeutic benefit. Thus, understanding the morbidity associated with PLND is important for counseling patients. We used the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) targeted prostatectomy database to quantify real-world 30-day postoperative outcomes of patients undergoing contemporary robot-assisted PLND at the time of RP for prostate cancer to quantify the incremental morbidity.

methodsWe conducted a retrospective cohort study using the NSQIP database of adult patients undergoing radical prostatectomy from 2019 to 2022. The primary outcomes were procedure-specific outcomes such as lymphocele and rectal injury. Secondary outcomes included a composite of any of the following 30-day major postoperative outcomes: mortality, reoperation, cardiac or neurologic event, as well as the individual components of this outcome, as well as infectious and other complications. We also analyzed yearly trends associated with PLND. Groups were balanced using propensity score matching (PSM) with a 1:1 ratio using demographic characteristics, prior medical history, and cancer staging data. Likelihood of complications was assessed by conditional logistic regression.

resultsWe identified 13,413 patients between 2019 and 2022 who underwent robotic prostatectomy: 11,341 (85%) had PLND while 2072 (15%) did not. After PSM, our cohort included 2071 matched pairs of patients with and without PLND. Patients who underwent PLND were more likely to be diagnosed with lymphocele (2.14% vs. 0.68%, OR 4.17; 95% CI 2.00, 8.68), have unplanned readmission (4.22% vs. 3.27%, OR 1.31; 95% CI 1.03, 1.65), and develop organ-site/space SSI (1.18% vs. 0.60%) (OR 1.97, 95% CI 1.20, 3.23). There was no significant association between the receipt of PLND and the likelihood of urinary leak or fistula, or ureteral obstruction. There were no significant differences between the two groups with respect to secondary outcomes of interest.

conclusionContemporary robotic PLND is associated with a 3-fold increased likelihood of lymphocele, as well as increased likelihood of unplanned readmission and organ-site SSI, though no significant differences in major postoperative complications were identified. We found that the odds of lymphoceles, readmission, and SSI in our study are lower than previously reported. These data provide real-world data to guide patient counseling and optimize patient selection for PLND at the time of RALP.

Indexed as

Lymph Node ExcisionPostoperative ComplicationsProstatectomyProstatic NeoplasmsRobotic Surgical ProceduresAgedDatabases, FactualHumansMaleMiddle AgedPelvisQuality ImprovementRetrospective Studieslymph nodeprostate cancerradical prostatectomyrobotic

Identifiers

PMID41294704
PMCPMC12650889

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.